Aerska secures $39 million to assist RNA medications in penetrating the brain.

      For families affected by neurodegenerative diseases, the most challenging aspect is not always the initial diagnosis. It is the gradual decline that follows: memory loss, changes in personality, and diminishing independence. This process happens quietly. It begins with missed appointments, followed by repeated questions, and then comes the unsettling moment when a once-familiar face no longer seems known.

      The disease does not just affect one individual; it reshapes the lives of those around them. Partners take on caregiving roles, children become responsible for decision-making, conversations become briefer, and patience wears thinner. Guilt sets in for feeling exhausted, for wishing for simpler times, and for yearning for the person who is still present in body but not in spirit.

      Neurodegeneration typically encompasses more than just one patient’s experience—it impacts the entire family, extending across kitchens, hospital hallways, and stretching out years that feel overly prolonged.

      Aerska, a company based in Dublin, has secured $39 million in new funding to tackle one of the largest scientific challenges preventing patients from receiving effective treatment: administering advanced genetic therapies directly to the brain.

      The funding round was co-led by EQT Life Sciences and age1, two investors known for supporting high-risk, high-reward biotech initiatives. Their investment is not merely in a platform but in the potential to intervene at the roots of diseases that have been managed primarily at their peripheries.

      Crossing the brain’s ultimate barrier

      Consider the brain as a secure house with stringent entrance protocols. This security mechanism, known as the blood-brain barrier, shields us from harmful substances in the bloodstream. However, its strictness also prevents many medications from entering.

      Consequently, even if researchers devise a sophisticated treatment capable of “turning off” a harmful gene associated with conditions like Alzheimer’s, the drug often cannot penetrate the brain cells it needs to affect.

      Aerska is working to overcome this access challenge. Instead of directly injecting medication into the brain—a process that carries risks—it aims to deliver it through the bloodstream like a conventional injection. Their technology functions as a special pass that enables treatments to cross the brain’s protective barrier. Once inside, the medication can decrease the production of the proteins that contribute to the disease.

      In simple terms, the science required to deactivate harmful genes is already established, but the real challenge lies in delivery. Aerska is focused on developing the necessary delivery system.

      The company initially concentrates on the genetic factors driving diseases such as Alzheimer’s and Parkinson’s, both of which currently lack cures. Existing medications primarily manage symptoms rather than alter the progression of these conditions.

      In contrast, RNA interference seeks to diminish the production of proteins that cause diseases, addressing the biological issue at its source rather than downstream.

      Longevity with practical implications

      The pursuit of longevity has become the “American dream” in European biotech; however, many serious investors are prioritizing healthspan—years spent with clarity and independence—over mere life extension.

      This is the market space Aerska is aiming to occupy. Their objective emphasizes not an abstract concept of immortality, but rather the desire for more time spent at home, familiar faces around, and maintained dignity.

      The $39 million raised will support preclinical advancements and early clinical endeavors. While significant scientific challenges remain, the field of neurological drug development has proven daunting for many. Nevertheless, if Aerska can demonstrate that systemic RNA delivery to the brain is both safe and effective, it would represent a fundamental shift in the approach to these diseases.

      For now, Aerska signifies something more straightforward: a European biotech firm willing to face one of medicine’s most persistent challenges, not merely through incremental symptom relief, but with the ambition to transform the very direction of these conditions.